CTLA4 and neoplasm: Antibodies against immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and its ligand PD-L1, and the cytotoxic lymphocyte antigen-4 (CTLA-4), temporarily blocks inhibitory signals of T cells, thereby strengthening activation of anti-tumor T cell responses 1,2.